Title 43 — Title 43 STATE GOVERNMENT—EXECUTIVE
178 chapters · 3,474 sections in this title.
RCW 43.71C.010 Definitions.
2.9K chars
*** CHANGE IN 2026 *** (SEE 5981-S2.SL) ***The definitions in this section apply throughout this chapter unless the context clearly requires otherwise.(1) "Authority" means the health care authority.(2) "Covered drug" means any prescription drug that:(a) A covered manufacturer in…
RCW 43.71C.020 Health carriers—Cost and utilization data reporting.
1.7K chars
Beginning October 1, 2019, and on a yearly basis thereafter, a health carrier must submit to the authority the following prescription drug cost and utilization data for the previous calendar year for each health plan it offers in the state:(1) The twenty-five prescription drugs m…
RCW 43.71C.030 Pharmacy benefit managers—Data reporting.
1.8K chars
(1) By March 1st of each year, a pharmacy benefit manager must submit to the authority the following data from the previous calendar year:(a) All discounts, including the total dollar amount and percentage discount, and all rebates received from a manufacturer for each drug on th…
RCW 43.71C.040 Pharmacy benefit managers—Compliance.
0.7K chars
(1) No later than March 1st of each calendar year, each pharmacy benefit manager must file with the authority, in the form and detail as required by the authority, a report for the preceding calendar year stating that the pharmacy benefit manager is in compliance with this chapte…
RCW 43.71C.050 Manufacturers—Data reporting.
2.8K chars
*** CHANGE IN 2026 *** (SEE 5981-S2.SL) ***(1) Beginning October 1, 2019, a covered manufacturer must submit to the authority the following data for each covered drug:(a) A description of the specific financial and nonfinancial factors used to make the decision to set or increase…
RCW 43.71C.060 Manufacturers—Notice of new drug applications.
1.6K chars
(1) Beginning October 1, 2019, a manufacturer must submit written notice, in a form and manner specified by the authority, informing the authority that the manufacturer has filed with the FDA:(a) A new drug application or biologics license application for a pipeline drug; or(b) A…
RCW 43.71C.070 Manufacturers—Notice of price increases.
1.3K chars
(1) Beginning October 1, 2019, a manufacturer of a covered drug must notify the authority of a qualifying price increase in writing at least sixty days prior to the planned effective date of the increase. The notice must include:(a) The date of the increase, the current wholesale…
RCW 43.71C.080 Pharmacy services administrative organizations—Data reporting.
0.8K chars
(1) Beginning October 1, 2019, and on a yearly basis thereafter, a pharmacy services administrative organization representing a pharmacy or pharmacy chain in the state must submit to the authority the following data from the previous calendar year:(a) The negotiated reimbursement…
RCW 43.71C.090 Enforcement.
0.5K chars
*** CHANGE IN 2026 *** (SEE 5981-S2.SL) ***The authority may assess a fine of up to one thousand dollars per day for failure to comply with the requirements of RCW 43.71C.020 through 43.71C.080. The assessment of a fine under this section is subject to review under the administra…
RCW 43.71C.100 Annual report—Data confidentiality.
2.5K chars
*** CHANGE IN 2026 *** (SEE 5981-S2.SL) ***(1) The authority shall compile and analyze the data submitted by health carriers, pharmacy benefit managers, manufacturers, and pharmacy services administrative organizations pursuant to this chapter and prepare an annual report for the…
RCW 43.71C.110 Rule making.
0.1K chars
The authority may adopt any rules necessary to implement the requirements of this chapter.[ 2019 c 334 s 13.]
RCW 43.71C.120 Information sharing.
0.2K chars
Information collected pursuant to this chapter may be shared with the health care cost transparency board established under chapter 70.390 RCW, subject to the same disclosure restrictions applicable under this chapter.[ 2024 c 80 s 6.]
RCW 43.71C.800 Joint state strategies—Development and implementation recommendations.
0.4K chars
The authority must contact the California office of statewide health planning and development and the Oregon department of consumer and business services to develop strategies to reduce prescription drug costs and increase prescription drug cost transparency. The authority must m…
RCW 43.71C.900 Findings—2019 c 334.
0.8K chars
The legislature finds that the state of Washington has substantial public interest in the following:(1) The price and cost of prescription drugs. Washington state is a major purchaser through the department of corrections, the health care authority, and other entities acting on b…